Research and Markets: Assess the Importance of Baxter's 'Wild Card' Gammagard for Alzheimer's Disease, Currently In Phase III Trials, In Driving Sales Growth Out To 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/cf74bc/baxter_internation) has announced the addition of the "Baxter International Inc.: PharmaVitae Profile" report to their offering.

This analysis examines the historical and forecast performance for Baxter in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Scope of Report:

  • Gain insight into Baxter's strategic outlook across the next 6 years
  • Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
  • Strategic insight into the prospects for Baxter over the next six years.
  • Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
  • Benchmark Baxter's performance against key rivals in the prescription pharmaceutical sector.
  • Assess the importance of Baxter's 'wild card' Gammagard for Alzheimer's disease, currently in Phase III trials, in driving sales growth out to 2015

Key Topics Covered:

  • Executive Summary
  • Prescription pharmaceutical sales and growth rate performance, 2003
  • Financial performance, 2003
  • Baxter: PharmaVitae forecasts at a glance
  • Strategic insight
  • Baxter's hold of the hemophilia market
  • Wild card Gammagard (CNS) essential for growth
  • SWOT analysis
  • ABOUT THIS PROFILE
  • PharmaVitae Explorer database
  • Chapter structure
  • Quarterly update
  • Company introduction
  • Company sales
  • Company financials
  • Key products
  • Data sourcing
  • Analyst consensus
  • QUARTERLY NEWS UPDATE
  • COMPANY INTRODUCTION
  • M&A history
  • Current corporate structure
  • COMPANY SALES
  • COMPANY FINANCIALS
  • KEY PRODUCTS
  • Overview
  • Advate/Recombinate
  • Antibody therapy (including Gammagard)
  • Gammagard (CNS)
  • Celvapan

For more information visit http://www.researchandmarkets.com/research/cf74bc/baxter_internation.

Source: Datamonitor

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716